Aytu BioPharma, Inc. — Form 10-K Summary
Reporting period: Fiscal year ended June 30, 2023. The request metadata says “2022 Q4,” but this filing is an annual report for FY2023, not a quarterly filing.
Business context
Aytu is a commercial-stage pharmaceutical company with two segments: prescription products (Rx) and consumer health products. Rx includes ADHD medicines Adzenys XR-ODT and Cotempla XR-ODT, plus a pediatric portfolio. Management is prioritizing Rx growth and expects to monetize, divest, or discontinue Consumer Health. Development of AR101 was indefinitely suspended; the Healight license was terminated and NT0502 rights were returned.
Financial performance and liquidity
| Metric | FY2023 | FY2022 |
|---|---|---|
| Net revenue | $107.4 million | $96.7 million |
| Gross profit / gross margin | $66.6 million / 62% | $52.3 million / 54% |
| Operating loss | $17.1 million | $109.9 million |
| Net loss | $17.1 million | $108.8 million |
| Cash used in operating activities | $5.1 million | $28.8 million |
| Cash and cash equivalents at year-end | $23.0 million | $19.4 million |
Rx revenue was $73.8 million, up from $61.1 million; Consumer Health revenue was $33.6 million, down from $35.5 million. Rx gross margin rose to 71% from 56%, while Consumer Health margin declined to 43% from 51%. Management attributed Rx growth mainly to competing ADHD-product shortages, the RxConnect program, and sales and marketing execution. Consumer Health revenue declined as the company reduced direct mail activity.
At June 30, 2023, current assets were $72.8 million and current liabilities $69.0 million. Accounts receivable was $28.9 million and inventory $12.0 million. Debt included a $15.0 million Avenue Capital term loan due January 2025 and $1.6 million drawn on the Eclipse revolving facility; the balance sheet reported $14.7 million of long-term debt, net of current portion. The company reported $6.4 million of derivative warrant liabilities.
The company reported a $304.1 million accumulated deficit. FY2023’s loss was substantially lower than FY2022’s, which included $65.8 million of goodwill impairment. FY2023 included $5.7 million of other asset impairment and approximately $2.4 million of inventory write-downs. A $4.8 million gain on derivative warrant liabilities partly offset other expense and is a fair-value, non-operating item.
Material changes versus the prior year
- Revenue increased 11% overall; Rx grew about 21%, while Consumer Health declined about 5%.
- Gross margin improved by 8 percentage points overall, mainly from higher Rx manufacturing utilization.
- Operating cash use fell by $23.7 million, but operations still consumed cash.
- Research and development expense fell to $4.1 million from $12.7 million as AR101 and Healight development was suspended or discontinued.
- The company raised approximately $15.6 million net through equity issuances during FY2023. Common shares outstanding were 5.5 million at year-end, after a 1-for-20 reverse split; substantial warrants were also outstanding.
Outlook, risks, and unusual items
Management provided no specific revenue, earnings, or cash-flow guidance. It expects to grow the Rx business, improve ADHD product margins through manufacturing transfers to a contract manufacturer, and reduce or exit Consumer Health. FDA approval for the Adzenys manufacturing transfer was obtained in April 2023; the Cotempla transfer application was submitted in June 2023, with approval anticipated by early calendar 2024. The company also announced a July 2023 distribution agreement for Adzenys and Cotempla in Israel and the Palestinian Authority; the filing says its financial effect could not yet be estimated.
Going concern: The auditor and management state that substantial doubt exists about the company’s ability to continue as a going concern. Management plans include cutting development costs, monetizing or winding down Consumer Health, refinancing the $15 million Avenue loan, and potentially raising capital or monetizing assets. The filing cautions that there is no assurance these plans will succeed.
- Debt and financing: Secured facilities have restrictive covenants and substantially all assets serve as collateral. Additional equity financing may dilute shareholders; warrant obligations and a dispute over warrant adjustments add potential dilution risk.
- Concentration: Three customers represented 78% of gross revenue and 83% of gross accounts receivable at year-end. One customer alone accounted for 43% of revenue.
- Execution and supply: Transferring ADHD manufacturing and maintaining supply of controlled Schedule II products involve regulatory, production, and DEA quota risks.
- Controls: The filing identifies a material weakness involving inventory valuation and reports disclosure controls were not effective. Its internal-control discussion also states management concluded internal control over financial reporting was effective, creating an apparent inconsistency that investors should review.
- Legal matters: The filing describes a warrant-related lawsuit and an employment lawsuit, whose outcomes and potential effects were not clear. A shareholder derivative matter was settled with governance changes and payment of plaintiff’s attorneys’ fees.
- Other risks: Generic competition, reimbursement pressure, inflation and supply-chain disruption, customer credit risk, and potential Nasdaq listing issues could affect results.
Important facts for investors to verify
- Whether the company can refinance or repay the Avenue loan by its January 2025 maturity and maintain compliance with lender covenants.
- Current cash, operating cash burn, and actual progress on Consumer Health monetization or discontinuation.
- FDA approval and operational timing for the Cotempla manufacturing transfer, and resulting cost and margin effects.
- Customer concentration, receivables collection, and assumptions behind gross-to-net revenue estimates; the auditor identified these estimates as a critical audit matter.
- The status and potential dilution from outstanding warrants, including the warrant-adjustment litigation.
- Remediation and independent testing of the inventory-valuation control weakness, and clarification of the filing’s differing control-effectiveness statements.